Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25968045 | 0.86 | LATS1 (0.34) | NFATC1GSK3BDYRK1A | |
| SCHEMBL25968044 | 0.84 | KAT2B (0.32) | HTR2AHTR2CHTR2BNFATC1GSK3B | |
| SCHEMBL15341875 | 0.81 | ADORA3 (0.38) | HTR2AHTR2CHTR2BNFATC1GSK3B | |
| SCHEMBL25966750 | 0.77 | HASPIN (0.35) | HTR2AHTR2CHTR2BDYRK1A | |
| SCHEMBL25968042 | 0.77 | MPO (0.42) | — | |
| SCHEMBL25979766 | 0.73 | HTR2A (0.35) | HTR2AHTR2CHTR2BNFATC1GSK3B | |
| SCHEMBL25971675 | 0.69 | DYRK1A (0.33) | HTR2AHTR2CHTR2BNFATC1GSK3B | |
| SCHEMBL25966728 | 0.67 | KAT2B (0.35) | NFATC1GSK3BDYRK1A | |
| SCHEMBL23229478 | 0.66 | DYRK1A (0.36) | HTR2AHTR2CHTR2BNFATC1GSK3B | |
| SCHEMBL31167733 | 0.66 | KDM5A (0.37) | NFATC1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR2A 1988/4885HTR2C 2900/4885HTR2B 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.